Premium
Targeting of C‐type lectin‐like receptor 2 or P2Y12 for the prevention of platelet activation by immunotherapeutic CpG oligodeoxynucleotides: reply
Author(s) -
Delierneux C.,
Donis N.,
Servais L.,
Wéra O.,
Lancellotti P.,
Oury C.
Publication year - 2018
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.13876
Subject(s) - p2y12 , cpg oligodeoxynucleotide , c type lectin , lectin , platelet , receptor , platelet activation , chemistry , cpg site , cancer research , medicine , immunology , biochemistry , platelet aggregation , gene , gene expression , dna methylation
In a recent issue of the Journal of Thrombosis and Haemostasis, we published a study demonstrating that phosphorothioate (PS)-modified CpG oligodeoxynucleotides (PS-CpG ODN) types A, B, and C activate platelets via CLEC-2 [1]. This study followed an initial article by Flierl et al. showing that PS-CpG ODN type C exerts platelet activating effect through GPVI [2]. In a Letter to the Editor, Flierl et al. now present new computational modeling data confirming that PS-CpG ODN type C can bind to CLEC-2 monomers or homodimers, or even to two homodimers, and would therefore be able to cause receptor clustering on platelet surface. This article is protected by copyright. All rights reserved.